{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Paralysie pseudobulbaire : Questions médicales les plus fréquentes",
"headline": "Paralysie pseudobulbaire : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Paralysie pseudobulbaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-02",
"dateModified": "2025-04-27",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Paralysie pseudobulbaire"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Paralysie",
"url": "https://questionsmedicales.fr/mesh/D010243",
"about": {
"@type": "MedicalCondition",
"name": "Paralysie",
"code": {
"@type": "MedicalCode",
"code": "D010243",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C23.888.592.636"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Paralysie pseudobulbaire",
"alternateName": "Pseudobulbar Palsy",
"code": {
"@type": "MedicalCode",
"code": "D020828",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Kenjiro Kunieda",
"url": "https://questionsmedicales.fr/author/Kenjiro%20Kunieda",
"affiliation": {
"@type": "Organization",
"name": "Neurology, Gifu University Graduate School of Medicine, Gifu, JPN."
}
},
{
"@type": "Person",
"name": "Tomohisa Ohno",
"url": "https://questionsmedicales.fr/author/Tomohisa%20Ohno",
"affiliation": {
"@type": "Organization",
"name": "Dentistry, Hamamatsu City Rehabilitation Hospital, Hamamatsu, JPN."
}
},
{
"@type": "Person",
"name": "Ichiro Fujishima",
"url": "https://questionsmedicales.fr/author/Ichiro%20Fujishima",
"affiliation": {
"@type": "Organization",
"name": "Rehabilitation Medicine, Hamamatsu City Rehabilitation Hospital, Hamamatsu, JPN."
}
},
{
"@type": "Person",
"name": "Victor Kekere",
"url": "https://questionsmedicales.fr/author/Victor%20Kekere",
"affiliation": {
"@type": "Organization",
"name": "Psychiatry, Interfaith Medical Center, Brooklyn, USA."
}
},
{
"@type": "Person",
"name": "Patrice Fouron",
"url": "https://questionsmedicales.fr/author/Patrice%20Fouron",
"affiliation": {
"@type": "Organization",
"name": "Psychiatry, Interfaith Medical Center, Brooklyn, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Cannabinoid Biosynthesis Using Noncanonical Cannabinoid Synthases.",
"datePublished": "2023-01-09",
"url": "https://questionsmedicales.fr/article/36674774",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms24021259"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cannabinoids in hyperhidrosis.",
"datePublished": "2022-10-18",
"url": "https://questionsmedicales.fr/article/36200741",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/09546634.2022.2127308"
}
},
{
"@type": "ScholarlyArticle",
"name": "Axially Chiral Cannabinoids: Design, Synthesis, and Cannabinoid Receptor Affinity.",
"datePublished": "2023-06-14",
"url": "https://questionsmedicales.fr/article/37314891",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/jacs.3c00129"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cannabinoids and synthetic cannabinoids as a cause of death: Trends and their healthcare implications.",
"datePublished": "2022-10-17",
"url": "https://questionsmedicales.fr/article/36250599",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/jnu.12817"
}
},
{
"@type": "ScholarlyArticle",
"name": "Chemistry and pharmacological aspects of furanoid cannabinoids and related compounds: Is furanoid cannabinoids open a new dimension towards the non-psychoactive cannabinoids?",
"datePublished": "2024-02-09",
"url": "https://questionsmedicales.fr/article/38417219",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejmech.2024.116164"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "États, signes et symptômes pathologiques",
"item": "https://questionsmedicales.fr/mesh/D013568"
},
{
"@type": "ListItem",
"position": 3,
"name": "Signes et symptômes",
"item": "https://questionsmedicales.fr/mesh/D012816"
},
{
"@type": "ListItem",
"position": 4,
"name": "Manifestations neurologiques",
"item": "https://questionsmedicales.fr/mesh/D009461"
},
{
"@type": "ListItem",
"position": 5,
"name": "Paralysie",
"item": "https://questionsmedicales.fr/mesh/D010243"
},
{
"@type": "ListItem",
"position": 6,
"name": "Paralysie pseudobulbaire",
"item": "https://questionsmedicales.fr/mesh/D020828"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Paralysie pseudobulbaire - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Paralysie pseudobulbaire",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Paralysie pseudobulbaire",
"description": "Comment diagnostique-t-on la paralysie pseudobulbaire ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels symptômes aident au diagnostic ?\nLa paralysie pseudobulbaire est-elle toujours associée à d'autres maladies ?\nPeut-on confondre cette paralysie avec d'autres troubles ?",
"url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Cannabinoids#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Paralysie pseudobulbaire",
"description": "Quels sont les principaux symptômes de la paralysie pseudobulbaire ?\nLa difficulté à parler est-elle un symptôme courant ?\nLes patients ressentent-ils de la douleur ?\nY a-t-il des variations dans les symptômes ?\nLes symptômes peuvent-ils s'aggraver avec le temps ?",
"url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Cannabinoids#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Paralysie pseudobulbaire",
"description": "Peut-on prévenir la paralysie pseudobulbaire ?\nComment réduire le risque de paralysie pseudobulbaire ?\nLes AVC peuvent-ils être prévenus ?\nLa réhabilitation précoce aide-t-elle à prévenir la paralysie ?\nLes habitudes alimentaires influencent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Cannabinoids#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Paralysie pseudobulbaire",
"description": "Quels traitements sont disponibles pour la paralysie pseudobulbaire ?\nLa rééducation est-elle utile ?\nLes médicaments peuvent-ils réduire les symptômes ?\nY a-t-il des traitements non médicamenteux ?\nLes traitements sont-ils efficaces pour tous les patients ?",
"url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Cannabinoids#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Paralysie pseudobulbaire",
"description": "Quelles complications peuvent survenir avec la paralysie pseudobulbaire ?\nLa dépression est-elle une complication fréquente ?\nLes complications affectent-elles la qualité de vie ?\nY a-t-il des risques d'isolement social ?\nLes complications peuvent-elles être traitées ?",
"url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Cannabinoids#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Paralysie pseudobulbaire",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de paralysie pseudobulbaire ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe mode de vie peut-il influencer le risque ?\nLes maladies cardiovasculaires sont-elles un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Cannabinoids#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on la paralysie pseudobulbaire ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen clinique et l'évaluation des symptômes neurologiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'imagerie cérébrale comme l'IRM peuvent être utilisés pour identifier les lésions."
}
},
{
"@type": "Question",
"name": "Quels symptômes aident au diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des accès de rire ou de pleurs inappropriés et des troubles de la parole."
}
},
{
"@type": "Question",
"name": "La paralysie pseudobulbaire est-elle toujours associée à d'autres maladies ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est souvent associée à des maladies neurologiques comme la sclérose en plaques ou les AVC."
}
},
{
"@type": "Question",
"name": "Peut-on confondre cette paralysie avec d'autres troubles ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec d'autres troubles affectant le contrôle émotionnel et moteur."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux symptômes de la paralysie pseudobulbaire ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux symptômes incluent des crises de rire ou de pleurs incontrôlables."
}
},
{
"@type": "Question",
"name": "La difficulté à parler est-elle un symptôme courant ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent éprouver des difficultés à articuler et à contrôler leur voix."
}
},
{
"@type": "Question",
"name": "Les patients ressentent-ils de la douleur ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "La paralysie pseudobulbaire ne cause généralement pas de douleur physique, mais des malaises émotionnels."
}
},
{
"@type": "Question",
"name": "Y a-t-il des variations dans les symptômes ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en intensité et en fréquence d'un patient à l'autre."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils s'aggraver avec le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, sans traitement, les symptômes peuvent s'aggraver et affecter la qualité de vie."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la paralysie pseudobulbaire ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais la gestion des maladies sous-jacentes peut aider."
}
},
{
"@type": "Question",
"name": "Comment réduire le risque de paralysie pseudobulbaire ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Adopter un mode de vie sain et traiter les affections neurologiques peut réduire le risque."
}
},
{
"@type": "Question",
"name": "Les AVC peuvent-ils être prévenus ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, en contrôlant les facteurs de risque comme l'hypertension et le diabète, on peut réduire les AVC."
}
},
{
"@type": "Question",
"name": "La réhabilitation précoce aide-t-elle à prévenir la paralysie ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une réhabilitation précoce après un AVC ou une lésion cérébrale peut aider à prévenir la paralysie."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles le risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée peut contribuer à la santé neurologique et réduire les risques."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour la paralysie pseudobulbaire ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments comme les antidépresseurs et la thérapie comportementale."
}
},
{
"@type": "Question",
"name": "La rééducation est-elle utile ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la rééducation orthophonique peut aider à améliorer les capacités de communication."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils réduire les symptômes ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent réduire la fréquence et l'intensité des épisodes émotionnels."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements non médicamenteux ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des approches comme la thérapie psychologique peuvent également être bénéfiques."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces pour tous les patients ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité des traitements peut varier selon les individus et la gravité des symptômes."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la paralysie pseudobulbaire ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles de la déglutition et des problèmes de communication."
}
},
{
"@type": "Question",
"name": "La dépression est-elle une complication fréquente ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent développer une dépression en raison de l'impact émotionnel de la maladie."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement altérer la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques d'isolement social ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les difficultés de communication peuvent entraîner un isolement social pour les patients."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être traitées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées avec des traitements appropriés et un soutien."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les AVC, les maladies neurodégénératives et les traumatismes crâniens sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de paralysie pseudobulbaire ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente avec l'âge, surtout chez les personnes âgées ayant des antécédents médicaux."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies neurologiques peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Le mode de vie peut-il influencer le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les maladies cardiovasculaires sont-elles un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les maladies cardiovasculaires augmentent le risque de paralysie pseudobulbaire par AVC."
}
}
]
}
]
}
From the Departments of Pediatrics and Neurology/Neurosurgery, McGill University; and Division of Pediatric Neurology, Montreal Children's Hospital-McGill University Health Centre, Canada. michael.shevell@muhc.mcgill.ca.
Division of Occupational Therapy and Physical Therapy, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, MLC 4007, Cincinnati, OH 45229, USA.
Faculty of Medicine (JPL), McGill University, Montreal, QC; Department of Pediatrics and Neurology and Neurosurgery (MO, MS), McGill University, Montreal, QC; Centre for Outcomes Research and Evaluation (MO, PN, MS), Research Institute of the McGill University Health Centre, Montreal, QC; Department of Pediatrics (JA), University of Alberta, Edmonton, AB; Janeway Children's Hospital (DB), St. John's, NL; Department of Paediatrics (DF), University of Toronto, Bloorview Research Institute, Toronto, ON; Departments of Pediatrics and Clinical Neurosciences (AK), Cumming School of Medicine, University of Calgary, AB; Centre de réadaptation Marie Enfant du CHU Sainte-Justine (LK), Montreal, QC; Centre hospitalier universitaire de Sherbrooke (NP), Sherbrooke, QC; BC Children's Hospital (EvR), Vancouver, BC; and IWK Health Centre (EW), Halifax, NS, Canada.
Clinical Department of Acupuncture and Moxibustion, First Teaching Hospital of Tianjin University of TCM, Tianjin 300380, China; National Clinical Research Center for Acupuncture and Moxibustion of Chinese Medicine, Tianjin 300380.
Clinical Department of Acupuncture and Moxibustion, First Teaching Hospital of Tianjin University of TCM, Tianjin 300380, China; National Clinical Research Center for Acupuncture and Moxibustion of Chinese Medicine, Tianjin 300380.
Clinical Department of Acupuncture and Moxibustion, First Teaching Hospital of Tianjin University of TCM, Tianjin 300380, China; National Clinical Research Center for Acupuncture and Moxibustion of Chinese Medicine, Tianjin 300380.
Clinical Department of Acupuncture and Moxibustion, First Teaching Hospital of Tianjin University of TCM, Tianjin 300380, China; National Clinical Research Center for Acupuncture and Moxibustion of Chinese Medicine, Tianjin 300380.
We report enzymes from the berberine bridge enzyme (BBE) superfamily that catalyze the oxidative cyclization of the monoterpene moiety in cannabigerolic acid (CBGA) to form cannabielsoin (CBE). The en...
Hyperhidrosis can significantly curtail patient quality of life, from debilitating physical symptoms to social stigmatization and reduced life opportunities. Current treatments often prove unsatisfact...
The resorcinol-terpene phytocannabinoid template is a privileged scaffold for the development of diverse therapeutics targeting the endocannabinoid system. Axially chiral cannabinols (...
Cannabis remains one of the most widely used illicit substances globally, with 188 million users in 2017. In the United States, nearly 50 million people are reported to have used cannabis in 2020. Mor...
The researchers used a retrospective design for this study....
We used the Florida Department of Law Enforcement data from 2014 to 2020 for this study. We used descriptive statistics to report the characteristics of decedents whose cause of death (COD) was associ...
A total of 386 decedents' COD in Florida was associated with CB and SC use. Nearly 28% of decedents were 45-54 years, male (87.8%), and non-Hispanic whites (65.3%). One hundred percent of CB-related d...
CBs and SCs as a COD pose a legitimate health problem to society. More people ages 45-54 died from CBs and SCs. Drug intoxications (from CBs and SCs) and motor vehicle collisions accounted for most of...
This study has clinical relevance to patient safety. CB and SC use contributes to motor vehicle accidents and can cause adverse effects including death....
Cannabinoids have emerged as compelling candidates for medicinal applications, notably following the recent approval of non-psychoactive cannabidiol (CBD) as a medicine. This endorsement has stimulate...
SummaryCannabis use is legalised in many countries. We present a patient in their 40s who complained of recurrent abdominal pain and associated nausea and vomiting. The patient was previously seen in ...
Pain, especially chronic pain, can strongly affect patients' quality of life. Cannabinoids ponhave been reported to produce potent analgesic effects in different preclinical pain models, where they pr...
On the basis of both scientific progress and popular lore, there is growing optimism in the therapeutic potential of cannabis (marijuana) and cannabinoid-based chemicals for movement disorders. There ...
In recognition of the high interest and controversial nature of this subject, the meeting committee of the International Parkinson and Movement Disorders Society arranged for a talk on cannabis at the...
The endocannabinoid system is strongly tied to motor function and dysfunction, with basic research suggesting several promising therapeutic targets related to cannabinoids for movement disorders. Clin...
Further research is greatly needed to better understand the actual clinical benefits and long-term side effects of medical cannabis products for movement disorders indications and populations....
Since ancient times, Cannabis and its preparations have found various applications such as for medical, recreational and industrial purposes. Subsequently the 1930s, legislation in many countries has ...